259214-55-6

Basic information

• Product Name: 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)-
• Synonyms: 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)-;Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, (1S,2R)-;(1S,2R)-1-(tert-butoxycarbonylaMino)-2-vinylcyclopropanecarboxylic acid;(1S,2R)-1-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid;1-[[(1,1-dimethylethoxy)carbo
• CAS NO: 259214-55-6
• Molecular Formula: C11H17NO4
• Molecular Weight: 142.18
• Mol File: 259214-55-6.mol

Chemical Properties

• Melting Point: 99-100.5 °C
• Boiling Point: 361°C at 760 mmHg
• Flash Point: 172.1°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 3.43E-06mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: 2-8°C
• PKA: 4.95±0.50(Predicted)
• CAS DataBase Reference: 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)-(259214-55-6)
• EPA Substance Registry System: 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)-(259214-55-6)

Safety Data

• Hazardous Substances Data: 259214-55-6(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)is used as a building block for the synthesis of novel pharmaceutical compounds due to its unique structure and functional groups. Its versatility allows for the development of new drugs with improved efficacy and selectivity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)is used as an intermediate in the synthesis of various drug candidates. Its specific stereochemistry and functional groups enable the creation of chiral molecules with potential therapeutic applications.
Used in Organic Synthesis:
1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-,(1S,2R)is utilized as a key intermediate in organic synthesis for the preparation of complex organic molecules. Its unique structure and functional groups facilitate the formation of new chemical entities with potential applications in various fields, such as materials science, agrochemicals, and specialty chemicals.

InChI:InChI=1/C11H17NO4/c1-5-7-6-11(7,8(13)14)12-9(15)16-10(2,3)4/h5,7H,1,6H2,2-4H3,(H,12,15)(H,13,14)/t7-,11-/m0/s1

Upstream product

• 1201943-62-5 1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 213316-49-5 (1RS,2SR)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 681807-59-0 (1R,2S)-ethyl 1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 924307-75-5 (1S,2R)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 787548-29-2 (1R,2S)/(1S,2R) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 1023795-84-7 C₂₁H₂₁NO₂ 
• 1393095-18-5 (E)-ethyl 1-(benzylideneamino)-2-vinylcyclopropanecarboxylate 

Downstream Products

• 1201943-62-5 (1S,2R)-1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 1446705-48-1 C₁₃H₁₂ClN₃O*C₇H₈O₃S 

Relevant articles and documents

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.